Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
The SGLT2i treated cohort experienced higher rates of diabetic ketoacidosis (DKA) (RR 2.08 [95% CI 1.05, 4.12] p =0.0309) and urinary tract infection/pyelonephritis (RR 2.27 [95% CI 1.12, 4.55] p =0.019) compared with the GLP-1 RA treated cohort
In more serious cases, it can affect the heart muscle or liver
Plus, some of them have short-chain fatty acids (SCFAs) that stimulate the production of GLP-1
10.1111/1759-7714.14151 98 LiuF.WangY.CaoY.WuZ.MaD.CaiJ.et al (2023)
He is also named co-inventor on two patents: U.S
Our team's assessment: the biological mechanisms involved don't suggest high-probability catastrophic toxicity, but they do suggest plausible pathways for subtle, cumulative effects that would only manifest after 612 months of continuous use
US$ 25.81
US$ 29.20
US$ 23.77
